ACP
CCXI

Acuta Capital Partners’s ChemoCentryx, Inc. CCXI Stock Holding History

Acuta Capital Partners’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-35,000
Closed -$1.38M – 45
2019
Q4 		$1.38M Buy
+35,000
New +$615K 0.34% 35

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acuta Capital Partners's CCXI Position: Q1 2020 in Review

Acuta Capital Partners sold out of ChemoCentryx, Inc. (CCXI) in Q1 2020, closing a stake of 35,000 shares — an estimated $1.38M sold.

Acuta Capital Partners first reported a position in CCXI in Q4 2019 and held it in 1 quarter. The position peaked at $1.38M in Q4 2019. 162 funds tracked by Wall St. Rank hold CCXI as of Q1 2020.

  • Acuta Capital Partners reported no remaining ChemoCentryx, Inc. position as of Q1 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 35,000 ChemoCentryx, Inc. shares in Q1 2020, an estimated $1.38M.
  • Acuta Capital Partners first reported a position in ChemoCentryx, Inc. in Q4 2019 and held it in 1 quarter.
  • Acuta Capital Partners's ChemoCentryx, Inc. position peaked at $1.38M in Q4 2019.
  • 162 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q1 2020.

Based on Acuta Capital Partners's 13F filing for Q1 2020, filed 15 May 2020.